CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Net loss	$ (145,940)	$ (112,418)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,034	2,867
Amortization and accretion income, net	(854)	(1,696)
Share-based compensation	31,861	23,519
Amortization of right-of-use assets	1,420	2,016
Amounts due from TRC, LLC	(6,934)	(14,595)
Interest shortfall on 2035 notes, net	1,093
Loss on extinguishment of debt	15,464
Other	(4)	53
Changes in operating assets and liabilities:
Accounts receivable		389
Receivables from collaborative and licensing arrangements	10,583	9,074
Other prepaid and current assets	(6,039)	(2,407)
Tax receivable	(300)	(3,700)
Other assets	(73)	2
Accounts payable	6,012	(5,491)
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(5,753)	(15,580)
Accrued interest payable	(1,957)	2,672
Deferred revenue	(12,120)	(12,826)
Operating lease liabilities	885	(1,371)
Other long-term liabilities	175	269
Net cash used in operating activities	(108,447)	(129,223)
Investing activities
Purchases of property and equipment	(3,322)	(1,796)
Purchases of marketable securities	(280,495)	(208,028)
Maturities of marketable securities	155,703	131,368
Proceeds from the sale of marketable securities	19,927
Proceeds from the sale of property and equipment	1
Proceeds from the sale of VIBATIV business, net		5,000
Net cash used in investing activities	(108,186)	(73,456)
Financing activities
Proceeds from the sale of ordinary shares, net	139,915
Proceeds from issuance of 2035 notes, net	380,000
Payment of issuance costs on 2035 notes	(5,326)
Payment of redemption premium on 2033 notes	(11,470)
Principal payment on 2033 notes	(235,347)
Proceeds from ESPP purchases	2,545	2,605
Proceeds from option exercises	936	2,545
Repurchase of shares to satisfy tax withholding	(7,948)	(2,181)
Net cash provided by financing activities	263,305	2,969
Net increase (decrease) in cash, cash equivalents, and restricted cash	46,671	(199,710)
Cash, cash equivalents, and restricted cash at beginning of period	58,897
Cash, cash equivalents, and restricted cash at end of period	105,568	179,144
Supplemental disclosure of cash flow information
Cash paid for interest	20,287	11,753
Cash paid for income taxes, net	$ 14	21
Right-of-use assets obtained in exchange for lease obligations (1)		$ 49,847